Dr. Agarwal’s Health Care, Share Price Target 2025, 2026, 2030
Dr. Agarwal’s Health Care founded in 2010, operates across India and several African countries. It offers various eye care services, including surgeries, consultations, and products. The company has seen strong growth, with most of its revenue from surgeries. With a growing demand for eye care, particularly in India and Africa, It is a well-positioned company for continued growth.
- 1 What is Dr. Agarwal’s Health Care NSE: AGARWALEYE?
- 2 Dr Agarwal’s Health Care Share Price Target Tomorrow
- 3 Dr Agarwal’s Health Care Share Price Target 2025
- 4 Dr Agarwal’s Health Care Share Price Target 2026
- 5 Share price Target 2027
- 6 Share price Target 2028
- 7 Share price Target 2029
- 8 Dr Agarwal’s Health Care share price Target 2030
- 9 Share price Target 2040
- 10 Share price Target 2050
- 11 Should I buy Dr Agarwal’s Health Care stock?
- 12 Dr Agarwal’s Health Care earning results (Financials)
- 13 Is Dr. Agarwal’s Health Care stock good to buy? (Bull case & bear case)
- 14 Conclusion
- 15 FAQs
What is Dr. Agarwal’s Health Care NSE: AGARWALEYE?
Dr. Agarwal’s Health Care was founded in 2010 by Dr. J. Agarwal in Chennai, Tamil Nadu, with a focus on providing high-quality eye care. The first hospital mainly treated eye conditions like cataracts, glaucoma, and refractive issues. Over the years, it expanded to offer a wider range of medical services and now has hospitals in many cities across India and other countries. It is known for its advanced technology, skilled doctors, and patient-focused care, this health care has become a trusted name in the healthcare industry, making healthcare affordable and accessible to many.
In FY24. 64.20% of its revenue came from surgeries, 12.83% from optical products, and the rest from eye care medicines. Between FY22 and FY24, its revenue grew by 38.34% annually, and its profit increased by 48.39%. The Indian eye-care market is expected to grow 12-14% annually, and the company’s hub-and-spoke model is expanding to underserved areas, with 123 facilities in Tier-II and Tier-III cities. This shows the company has strong fundamentals with are very important for investment.
| Day | Minimum Price (Rs) | Maximum Price (Rs) |
| Tomorrow | -27 | +60 |
The company is expected to experience steady growth as it continues expanding its network and enhancing its medical capabilities. The company’s success in treating over 21 lakh patients and performing over 220,000 pulse surgeries in the past year will likely attract investor attention.
With an increasing share of revenue coming from surgical procedures, along with a growing base of satisfied patients, the share price is expected to gradually rise. The company’s focus on high-quality services and its reputation as a trusted name in eye care will play a key role in boosting its market value. In 2025, its share price target would be ₹617, as per our analysis.
By our prediction, its share price would be between ₹328 to ₹617 in 2025.
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
| 2025 | 328 | 617 |
| Month | Minimum Price (Rs) | Maximum Price (Rs) |
| January | — | — |
| February | 365 | 464 |
| March | 367 | 490 |
| April | 345 | 500 |
| May | 328 | 534 |
| June | 400 | 565 |
| July | 435 | 578 |
| August | 478 | 590 |
| September | 500 | 632 |
| October | 525 | 649 |
| November | 554 | 654 |
| December | 587 | 660 |
This company has already made good progress in expanding across India, with more than 193 facilities in 117 cities. The company’s plan to open more Centers of Excellence, which offer advanced surgeries and training programs, will help it grow. As the need for eye care services increases, especially in smaller cities, the company’s efficient way of expanding into new areas will likely boost its share price. In 2026, its stock price target would be ₹767 as per our analysis.
By our prediction, its stock price would be between ₹530 to ₹767 in 2026.
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
| 2026 | 530 | 767 |
| Month | Minimum Price (Rs) | Maximum Price (Rs) |
| January | 660 | 600 |
| February | 530 | 620 |
| March | 557 | 639 |
| April | 579 | 655 |
| May | 591 | 673 |
| June | 608 | 680 |
| July | 637 | 690 |
| August | 643 | 700 |
| September | 667 | 728 |
| October | 683 | 739 |
| November | 720 | 746 |
| December | 738 | 767 |
The company’s focus on growing both naturally and by acquiring new facilities should lead to stronger financial performance. As the company continues to expand its presence in key areas, it will be able to capture more market share. This growth in infrastructure and reach will likely result in higher revenue and better efficiency, which can drive up the share price. With its trusted brand and leadership from experienced doctors, the company will also remain an attractive option for investors. In 2027, its stock price target would be ₹900 as per our analysis.
By our prediction, its stock price would be between ₹738 to ₹900 in 2027.
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
| 2027 | 738 | 900 |
| Month | Minimum Price (Rs) | Maximum Price (Rs) |
| January | 738 | 780 |
| February | 751 | 800 |
| March | 768 | 810 |
| April | 789 | 820 |
| May | 800 | 838 |
| June | 818 | 845 |
| July | 830 | 861 |
| August | 843 | 870 |
| September | 840 | 865 |
| October | 855 | 878 |
| November | 850 | 883 |
| December | 871 | 900 |
With the Indian eye care market expected to grow a lot in the next few years, the company is in a great position to take advantage of this growth. Its focus on expanding into emerging markets like Africa, where the demand for healthcare is rising, will help its global expansion. Also, its strong financial performance in recent years will likely increase investor confidence in the company’s future growth. So in 2028, its stock price target would be ₹1089 as per our analysis.
By our analysis, its stock price would be between ₹ 870to ₹1089 in 2028.
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
| 2028 | 870 | 1089 |
| Month | Minimum Price (Rs) | Maximum Price (Rs) |
| January | 871 | 921 |
| February | 885 | 943 |
| March | 897 | 968 |
| April | 910 | 980 |
| May | 941 | 963 |
| June | 955 | 983 |
| July | 968 | 997 |
| August | 980 | 1010 |
| September | 997 | 1024 |
| October | 1012 | 1038 |
| November | 1030 | 1068 |
| December | 1056 | 1089 |
The company is investing in training, advanced technology, and new surgeries like robotic cataract surgery, which will help improve its reputation for high-quality care. As the demand for eye care in India keeps rising, the company’s growing number of patients and continued expansion will likely lead to steady revenue growth. As the company becomes financially stronger, its share price is expected to increase due to the rising demand for its eye care services. By 2029, its stock price target would be ₹1290 as per our analysis.
As per our prediction, its stock price would be between ₹1056 to ₹1290 in 2029.
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
| 2029 | 1056 | 1290 |
| Month | Minimum Price (Rs) | Maximum Price (Rs) |
| January | 1056 | 1100 |
| February | 1073 | 1121 |
| March | 1089 | 1143 |
| April | 1097 | 1167 |
| May | 1127 | 1178 |
| June | 1139 | 1183 |
| July | 1158 | 1198 |
| August | 1178 | 1210 |
| September | 1190 | 1228 |
| October | 1218 | 1236 |
| November | 1228 | 1270 |
| December | 1255 | 1290 |
With more hospitals and medical centres opening, especially in growing markets, the company is set for long-term success. By focusing on new surgical treatments and keeping patients satisfied, the company should keep growing in both revenue and share price. As the demand for eye care increases in India and the company expands internationally, it will strengthen its position as a leader in the industry, which will likely boost its stock value. In 2030, its stock price target would be ₹1569 as per our analysis.
By our prediction, its stock price would be between ₹1255 to ₹1569 in 2030.
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
| 2030 | 1255 | 1569 |
| Month | Minimum Price (Rs) | Maximum Price (Rs) |
| January | 1255 | 1300 |
| February | 1283 | 1320 |
| March | 1298 | 1331 |
| April | 1318 | 1340 |
| May | 1328 | 1353 |
| June | 1340 | 1370 |
| July | 1354 | 1390 |
| August | 1368 | 1437 |
| September | 1383 | 1480 |
| October | 1355 | 1520 |
| November | 1456 | 1550 |
| December | 1520 | 1569 |
This company is expected to remain a leader in the global eye care market. The company’s ability to expand into fast-growing areas while continuing to innovate in surgeries will help it stay ahead of competitors. As it grows in underserved areas, both in India and globally, the company’s share price is likely to show its long-term value. Its flexible business model and focus on improving patient care will help it remain an industry leader, making its stock a good long-term investment. So by 2040, its stock price target would be ₹3410 as per our analysis.
By our prediction, its stock price would be between ₹2970 to ₹3410 in 2040.
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
| 2040 | 2970 | 3410 |
| Month | Minimum Price (Rs) | Maximum Price (Rs) |
| January | 2970 | 3020 |
| February | 2990 | 3037 |
| March | 3010 | 3060 |
| April | 3037 | 3088 |
| May | 3055 | 3120 |
| June | 3080 | 3160 |
| July | 3125 | 3210 |
| August | 3180 | 3258 |
| September | 3210 | 3280 |
| October | 3239 | 3334 |
| November | 3310 | 3380 |
| December | 3350 | 3410 |
It is likely to become a well-known brand around the world, with a strong presence in both developed and growing markets. The company’s plan to expand into areas with less access to eye care and focus on new eye care technology will help it stay ahead of competitors. As it continues to grow and meet the increasing need for eye care, its share price is expected to increase. Investors can expect good returns from this company because of its strong reputation and leadership in the eye care field. In 2050, its stock price target would be ₹5630 as per our analysis.
By our prediction, its stock price would be between ₹4842 to ₹5630 in 2050.
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
| 2050 | 4842 | 5630 |
| Month | Minimum Price (Rs) | Maximum Price (Rs) |
| January | 4842 | 4873 |
| February | 4860 | 4930 |
| March | 4884 | 4963 |
| April | 4928 | 4980 |
| May | 4955 | 5020 |
| June | 4980 | 5039 |
| July | 5010 | 5090 |
| August | 5046 | 5180 |
| September | 5150 | 5278 |
| October | 5250 | 5390 |
| November | 5355 | 5510 |
| December | 5450 | 5630 |
Should I buy Dr Agarwal’s Health Care stock?
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
| 2025 | 328 | 617 |
| 2026 | 530 | 767 |
| 2027 | 738 | 900 |
| 2028 | 870 | 1089 |
| 2029 | 1056 | 1290 |
| 2030 | 1255 | 1569 |
| 2040 | 2970 | 3410 |
| 2050 | 4842 | 5630 |
It has great growth potential with its expanding presence, especially in places like India and Africa where eye care is in high demand. The company is also investing in new technology and surgeries, which will help it grow even more. If you’re interested in a long-term investment in the healthcare sector, this stock might be a good choice. However, make sure to do your research or talk to a financial advisor before deciding.
Dr Agarwal’s Health Care earning results (Financials)
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
| Sales + | 176 | 140 | 201 | 268 | 319 |
| Expenses + | 129 | 109 | 143 | 192 | 227 |
| Operating Profit | 47 | 31 | 59 | 76 | 92 |
| OPM % | 27% | 22% | 29% | 28% | 29% |
| Other Income + | 3 | 1 | 1 | 2 | 5 |
| Interest | 9 | 7 | 7 | 8 | 8 |
| Depreciation | 21 | 19 | 20 | 20 | 27 |
| Profit before tax | 20 | 6 | 32 | 49 | 62 |
| Tax % | 31% | 125% | 25% | 25% | 26% |
| Net Profit + | 14 | -1 | 24 | 37 | 46 |
| EPS in Rs | 29.11 | -3.06 | 51.28 | 78.55 | 98.64 |
| Dividend Payout % | 0% | 0% | 6% | 4% | 3 |
Is Dr. Agarwal’s Health Care stock good to buy? (Bull case & bear case)
Bull Case
- 31.4% profit growth over the last 5 years.
- Impressive 36.1% ROE over 3 years.
- Trusted brand with strong expansion in India and Africa.
- Investing in advanced surgeries like robotic cataract surgery.
Bear Case
- The stock is trading at 15.4 times its book value, which may be overvalued.
- Possible concern about financial transparency.
- Promoters have pledged 55.4% of their stake, adding financial risk.
- Paying off some or all of its loans.
Conclusion
This has good growth potential with its expansion in India and Africa, plus investments in new technology. However, the stock might be a bit expensive, and there are some concerns about financial transparency and the promoters’ pledged shares. We have details about this stock in this article. It could be a good long-term investment, but it’s important to do your research before buying.
